Hematological malignancy- a
term specified to a set of cancers that hit and affects the bone marrow, lymph
nodes and blood. Generally, the patients who suffer from Lymphomas, Myelomas
and Leukemia are not able to discover a permanent treatment for their illness
and do not survive the condition.
However, the latest
advancements prove that gene therapy can be an exceptional development for the
cure of various types of blood cancers. Researchers are positive about the
usage of gene therapy in which the blood cells can actually be used to attack
the cancerous cells. The testing’s, up till now have given promising outcomes
and the patients does not show any signs and symptoms of cancer, after this
medical treatment. This is genuinely accurate even for the myeloma, chronic
lymphocytic leukemia and lymphocytic leukemia patients who were taking regular
chemotherapies for years:
“Cancer
was so advanced in 8-year-old Emily Whitehead of Philipsburg, Pa., that doctors
said her major organs would fail within days. She was the first child given the
gene therapy and shows no sign of cancer today, nearly two years later.”
In this treatment, the
doctors are actually sorting out the white blood cells from the blood in
massive quantities. These cells are then
introduced in a lab to a particular gene targeting cancer, and then are induced
back in the patient’s blood over a period of three days. This way, cancer is
treated successfully and in a more productive method than chemotherapies, bone
marrow transplants or stem cell.
Current
Gene Therapy is a conventional, bi-monthly peer-reviewed journal from the
shelves of Bentham Science Publishers. It has an impact factor rating, (5.318) and
is indexed in major abstracting agencies, that includes; Scopus,
EMBASE, MEDLINE/Index Medicus, and Journal Citation Reports etc. Current
Gene Therapy publishes major topics concerning basic and clinical applications
of gene and cell therapy. http://benthamscience.com/cgt/
No comments:
Post a Comment